Introduction

In oncology, the accurate detection of somatic mutations is essential for guiding effective cancer management and personalized treatment. The ViennaLab Somatic Mutations NGS Assay delivers a powerful solution for identifying clinically relevant mutations across a broad spectrum of cancer-associated genes, supporting laboratories and clinicians in precision oncology.

Broad Spectrum of Cancer-Associated Genes

The Somatic Mutations NGS Assay targets a curated panel of genes commonly linked to tumor development, progression, and therapeutic response. These include:

ALK, APC, BRAF, EGFR, ERBB2, KRAS, MET, NRAS, PIK3CA, RET, ROS1, SMAD4, TP53

By covering these high-value targets, the assay enables comprehensive detection of somatic mutations that drive cancer, ensuring clinically actionable insights.

Detection of Variants and Target Regions

The ViennaLab Somatic Mutations NGS Assay is designed to detect:

• Single Nucleotide Variants (SNVs)
• Insertions and Deletions (InDels)
• Gene Fusions

Targeted regions span the complete Coding Sequence (CDS) and selected hotspot introns, covering 62 kb. This allows for robust identification of somatic mutations across key cancer pathways.

Integrated Bioinformatics for Clear Results

Through integrated analysis with GENOVESA bioinformatics software, the assay transforms raw sequencing data into clinically relevant reports. This streamlined approach helps laboratories reduce turnaround times while ensuring accuracy in reporting somatic mutation profiles.

Clinical Relevance and Applications

The ViennaLab Somatic Mutations NGS Assay empowers personalized oncology by identifying mutations that inform therapy selection, resistance mechanisms, and prognosis. By focusing on the genetic changes most relevant to cancer biology, it provides clinicians with reliable insights for patient-specific treatment strategies.

Conclusion

The ViennaLab Somatic Mutations NGS Assay is a critical tool for modern oncology, enabling the precise detection of a wide range of somatic mutations associated with cancer. With its extensive gene panel, advanced mutation detection capabilities, and integrated bioinformatics, it offers laboratories and clinicians a robust solution for advancing precision medicine in cancer diagnostics.